Live tape
Top 8, mentions 7d183GOOGL30 mentions+0.01INTC29 mentions▲ +0.16NVDA27 mentions▲ +0.08SPY22 mentions+0.00VOO20 mentions▲ +0.04NKE19 mentions-0.01RBA19 mentions▲ +0.05MSFT17 mentions▲ +0.05

Equity · Healthcare

GTBP

GT Biopharma, Inc. · NasdaqCM

$0.35 −8.05% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 17 sessions
$0.50 $0.30 24 Jun 17 Jul

The line runs $0.46 on 24 June through $0.35 on 17 July, on a scale from $0.30 to $0.50. Days the market did not trade hold the previous close, flat.

The chart above plots the price of GTBP over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 17 sessions over that window: $0.46 on 24 June 2026 through $0.35 on 17 July 2026.

Market cap $16.0M
Avg volume 153.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 21, 2026

GTBP insider trades

SEC Form 4

GTBP has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 4 September 2025.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
04 Sep 2025 Kramer Hilary Award 31,250
04 Sep 2025 Breen Michael Martin CEO and Director Award 100,000
04 Sep 2025 Mun-Gavin David C. Award 31,250
04 Sep 2025 CASAMENTO CHARLES J Award 62,500
04 Sep 2025 URBAN ALAN LOUIS Chief Financial Officer Award 50,000

GTBP reported financials

SEC EDGAR XBRL

GTBP reported net income of −$28.4M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$28.4M 31 Dec 2025 fiscal year
Diluted EPS −$6.68 31 Dec 2025 fiscal year
Total assets $8.1M 31 Dec 2025 at period end
Total equity $3.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

GTBP earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.12
31 Mar 2026 Q1 2026 $-0.11
31 Dec 2025 FY 2025 $-6.68
30 Sep 2025 FY 2025 $1.04
30 Jun 2025 FY 2025 $-10.92
31 Mar 2025 Q1 2025 $-0.33
31 Dec 2024 FY 2024 $-6.94
30 Sep 2024 Q3 2024 $-1.53

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

GTBP institutional holders

SEC Form 13F

0 of the 45 institutional funds we track reported a GTBP position for the quarter ended 30 Jun 2026; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value

Source: SEC EDGAR 13F filings

GTBP fails-to-deliver

SEC CNS data

On 31 Aug 2026, 22,999 shares of GTBP failed to deliver (about $7K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
31 Aug 2026 22,999 $7K 0.051%
28 Aug 2026 499 $150 0.001%
26 Aug 2026 1,000 $300 0.002%
25 Aug 2026 1,000 $310 0.002%
18 Aug 2026 19,260 $6K 0.043%
17 Aug 2026 14,900 $4K 0.033%
14 Aug 2026 46,673 $14K 0.103%
13 Aug 2026 14,900 $4K 0.033%
12 Aug 2026 14,900 $5K 0.033%
11 Aug 2026 14,900 $5K 0.033%
10 Aug 2026 14,900 $5K 0.033%

Source: SEC fails-to-deliver (CNS) data